Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

By R. Motzer, J. Bacik, Lawrence H. Schwartz, V. Reuter, P. Russo, S. Marion, M. Mazumdar. Journal of Clinical Oncology, 2004

761 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/d2fe96277df1fa2349c983e7a9904a19ce258056

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. C. Porta

Citations in the corpus

• Sunitinib in patients with metastatic renal cell carcinoma. (2006, neutral): “‡Motzer et al 2004.”
• Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010, methodology): “MSKCC risk status in previously treated patients.(4) Dummy coding was performed with 2 binary variables using the”
• EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “Clinical factors include patient PS, localised symptoms, cachexia, anaemia, elevated neutrophil and platelet counts, and other laboratory parameters, and are predominantly used in prognostic risk models in mRCC (LE 3) [48] [49].”
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, neutral): “This PFS benefit was independent of gender, age, prior therapy, MSKCC (Memorial Sloan-Kettering Memorial Cancer Center) risk grou”